Tag: single-use technologies
How Process Enabling Closed Systems Offer Maximum Safety in ADC Manufacturing
Since Antibody-drug Conjugates (ADC) are already approved for the treatment of relapsed Hodgkin’s lymphoma, HER2-positive metastatic breast cancer and B cell lymphoma, among others, high expectations are placed on this class of bioconjugates. Indeed, more than 100 different ADCs have been studied for various applications by 2022, presumably with several more to follow.
Recorded Webinar – Single-use TFF Capsules for mAb and ADC Processing
Recorded: February 22, 2018
Speaker: April Wheeler, Technology Manager, TFF and Clarification
Title: Single-use TFF Capsules for mAb and ADC Processing
Abstract: The need to increase manufacturing...
Lonza Expands it’s Mammalian Production Capacity
Over the last decade, biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), therapeutic proteins, immunotherapeutics, and therapeutic (cancer) vaccines have greatly transformed treatment of...
